1. Review recent pathophysiological findings in AD that have informed the selection of new therapeutic targets

2.Describe best practices for severity assessment and diagnosis of moderate-to-severe AD in pediatric patients, accounting for biomarkers, phenotype/genotype, comorbidities, and disease burden

3. Explain the mechanisms of action and clinical profiles of new and emerging targeted systemic agents for the long-term treatment of AD in pediatric patients


Session date: 
02/07/2019 - 12:00pm to 1:00pm CST
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Peter Lio, M.D.